Development of novel biomarkers of colorectal cancer using 3D microenvironment construction model
| Project/Area Number |
17K16564
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | National Hospital Organization, Kyushu Cancer Center |
|---|
Principal Investigator |
Sugiyama Masahiko 独立行政法人国立病院機構(九州がんセンター臨床研究センター), その他部局等, 消化管外科医師 (40751079)
|
|---|
| Project Period (FY) |
2017-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 大腸癌 / 腫瘍免疫 / 癌幹細胞 / 免疫療法 / 腫瘍局在 / 医療 |
|---|
| Outline of Final Research Achievements |
For the cancer that has acquired immune immune resistance, treatment with immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 has been applied clinically. On the other hand, in colon cancer, it is known that the effect of molecular inhibitors on immune checkpoints using molecular blocking mechanisms is limited. We performed analysis for the expression of molecules related to genetic instability and tumor immunoresistance in colorectal cancer. As a result, we clarified that antigen presentation and tumor immune response were performed at the tumor advanced site in cases with high genetic instability, and identified several prognostic factors in clinicopathologically.
|
| Academic Significance and Societal Importance of the Research Achievements |
本邦における大腸癌の罹患率、死亡率は年々増加しており、治療に寄与するための病態解明が急務とされています。一方で複数の癌種において腫瘍の免疫抵抗性を解除することによって抗腫瘍免疫の再活性化をおこなう治療法が既に臨床の現場にもたらされており、多くの患者さんに福音となっています。大腸癌においても遺伝子不安定性の高い症例において治療が始まっています。
本研究は大腸癌と抗腫瘍免疫にかかわる分子の関わりの一端を臨床病理学的に明らかにしました。今後の大腸癌に対する抗腫瘍免疫治療の一助のなることが期待されます。しかし大腸癌に対する抗腫瘍免疫の効果は限定的であることからさらなる解明が求められることがわかりました。
|
Report
(3 results)
Research Products
(24 results)
-
-
[Journal Article] Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist.2018
Author(s)
Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, Satake H, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Sugiyama M, Komatsu Y, Okuyama H, Baba E, Sakai D, Watanabe T, Tamura T, Yamashita K, Gosho M, Shimada Y.
-
Journal Title
Oncologist.
Volume: 23
Pages: 7-15
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
